Compositions and methods of treating T cell mediated disorder
A method of generating a CD4 + FoxP3 + Treg cell, the method includes administering at least one complement antagonist to a naive CD4 + T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4 + T cell, induce TGF-β1 expression of the CD4 + T cell, and induce differentiation of the of the naive CD4 + T cell into a CD4 + FoxP3 + Treg cell.
1. A method of generating a CD4 + FoxP3 + Treg cell, the method comprising:
isolating a naive CD4 + T cell;
culturing the naive CD4 + T cell in the presence of dendritic cells or antigen presenting cells, anti-CD3, and IL 2; and
administering a C3a antagonist or C3aR antagonist and a C5a antagonist or C5aR antagonist to the naive CD4 + T cell at an amount effective to substantially inhibit interaction of C3a and C5a with the C3aR and C5aR of the CD4 + T cell, induce TGF-β1 expression of the CD4 + T cell, and induce differentiation of the of the naive CD4 + T cell into a CD4 + FoxP3 + Treg cell.
2. The method of claim 1 , the C3a antagonist or C3aR antagonist and the C5a antagonist or C5aR antagonist being selected from the group consisting of a small molecule, a polypeptide, and a polynucleotide.
3. The method of claim 2 , the polypeptide comprising an antibody directed against at least one of C3a, C5a, C3aR, or C5aR.
4. The method of claim 2 , the polynucleotide comprising a small interfering RNA directed against a polynucleotide encoding at least one of C3, C5, C3aR, or C5aR.
5. The method of claim 1 , the step of administering the complement antagonist includes administering to the naive CD4 + T cell a C3aR antagonist and a C5aR antagonist.
6. The method of claim 5 , wherein the C3aR antagonist and the C5aR antagonist are antibodies.
7. The method of claim 1 , the step of administering the at least one complement antagonist includes administering to the naïve CD4 + T cell a C3a antagonist and a C5a antagonist.
8. The method of claim 7 , wherein the C3a antagonist and C5a antagonist are antibodies.
9. The method of claim 1 , the naive CD4 + T cell comprising a human CD45 hi CD44 low CD4 + T cell.
10. The method of claim 1 , wherein the complement antagonist substantially induces naive CD4+ cell expression of CD25, CTLA-4, FoxP3, DAF and C5L2, downregulates dendritic cell B7/CD40 and CD4+ effector cell CD28/CD40 ligand costimulatory molecule expression, and inhibits dendritic cell C5a/C3a production and CD4 + cell C5aR/C3aR signal transduction.
11. The method of claim 1 , wherein the antigen presenting cells are dendritic cells.
12. A method of treating a T cell mediated autoimmune disorder or disease in a subject comprising:
culturing a naive CD4 + T cell in the presence of or antigen presenting cells, anti-CD3, and IL-2; and
administering a C3a antagonist or a C3aR antagonist and a C5a antagonist or a C5aR antagonist to the naive CD4 + T cell at an amount effective to substantially inhibit interaction of C3a and C5a with the C3aR and C5aR of the CD4 + T cell, induce TGF-β1 expression of the CD4 + T cell, and induce differentiation of the of the naive CD4 + T cell into a CD4 + FoxP3 + Treg cell; and
administering a therapeutically effective amount of the CD4 + FoxP3 + Treg cells to the subject.
13. The method of claim 12 , the step of administering the complement antagonist includes administering to the naive CD4 + T cell a C3aR antagonist and a C5aR antagonist.
14. The method of claim 12 , the step of administering the at least one complement antagonist includes administering to the CD4 + T cell a C3a antagonist and a C5a antagonist.
15. The method of claim 12 , the CD4 + FoxP3 + Treg cells being administered systemically to the subject being treated.
16. The method of claim 12 , wherein the antigen presenting cells are dendritic cells.